TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05671783

Intervention type: OTHER
Intervention: Hemodynamic observation of the patients.
Description: For the purposes of this study, we defined intraoperative hypotension as a decrease in mean blood pressure of 30% from baseline for a minimum of 5 minutes, including induction and maintenance of anesthesia. The measuring blood pressure method (noninvasive or invasive) depended on the surgical intervention's invasiveness and the patient's cardiac performance.~As soon as the patients entered the PACU, the responsible nurses started the standard monitoring. Anesthesiologists constantly oversee all actions based on the patient's condition. Clinical observation for respiratory and gastrointestinal problems and all disorders were monitored. When in room air SO2 was \<94, we started oxygen treatment with a 4 liter/minute nasal cannula, and in cases of nausea antiemetic was administered. The Modified Aldrete Score was used to discharge the patent.

Intervention type: OTHER
Intervention: Hemodynamic observation of the patients.
Description: For the purposes of this study, we defined intraoperative hypotension as a decrease in mean blood pressure of 30% from baseline for a minimum of 5 minutes, including induction and maintenance of anesthesia. The measuring blood pressure method (noninvasive or invasive) depended on the surgical intervention's invasiveness and the patient's cardiac performance.~As soon as the patients entered the PACU, the responsible nurses started the standard monitoring. Anesthesiologists constantly oversee all actions based on the patient's condition. Clinical observation for respiratory and gastrointestinal problems and all disorders were monitored. When in room air SO2 was \<94, we started oxygen treatment with a 4 liter/minute nasal cannula, and in cases of nausea antiemetic was administered. The Modified Aldrete Score was used to discharge the patent.

Intervention type: OTHER
Intervention: Hemodynamic observation of the patients.
Description: For the purposes of this study, we defined intraoperative hypotension as a decrease in mean blood pressure of 30% from baseline for a minimum of 5 minutes, including induction and maintenance of anesthesia. The measuring blood pressure method (noninvasive or invasive) depended on the surgical intervention's invasiveness and the patient's cardiac performance.~As soon as the patients entered the PACU, the responsible nurses started the standard monitoring. Anesthesiologists constantly oversee all actions based on the patient's condition. Clinical observation for respiratory and gastrointestinal problems and all disorders were monitored. When in room air SO2 was \<94, we started oxygen treatment with a 4 liter/minute nasal cannula, and in cases of nausea antiemetic was administered. The Modified Aldrete Score was used to discharge the patent.
Study: NCT04654481

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HCFWO
Description: The Afflovest device is a High Frequency Chest Wall Oscillation (HFCWO) device, a medical vest that uses vibrations to loosen and mobilize mucus in the lung secretions and help clear the airways.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care Plus Monitoring
Description: Monitoring via home spirometry, pulse oximetry, temperature checks, telehealth check-in and patient-reported outcome assessments.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care Plus Monitoring
Description: Monitoring via home spirometry, pulse oximetry, temperature checks, telehealth check-in and patient-reported outcome assessments.
Study: NCT05374382

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strengthening
Description: 3x/w, 9 wks supervised strengthening program, during prehabilitation to ACL surgery

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional
Description: Participants received a 9-weeks conventional prehabilitation program (targeting pain knee mobility) before ACL reconstruction, followed by a standardized post-operative rehabilitation program
Study: NCT04506814

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endocardial PVI
Description: Catheter based PVI

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epicardial Posterior Wall Isolation + LAA Exclusion + Endocardial PVI
Description: Minimally invasive PVI with posterior wall RF ablation + LAA clip + endocardial PVI
Study: NCT05744622

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KetacTM Universal AplicapTM
Description: chemically cured conventional GICs

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KetacTM Universal AplicapTM with light cure
Description: chemically cured conventional GICs with light curing enhancement
Study: NCT05811715

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whole body stretching excercise
Description: For the WBS group, each 30 minutes exercise class was run by a one trained physiotherapist to serve a maximum of 10 participants (10 x 3 = 30 participants) working in the hospital. Participants invited to attend the exercise class 3 times a week for 6 weeks in their hospital during lunch-break. During each session, participants asked to perform WBS exercise (Franco et al., 2008).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational program
Description: Participants received an education program which includes ergonomic principles, WRMSDs and their risk factors, as well as manual handling techniques(Bolbol et al., 2017).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: educational program
Description: Participants received an education program which includes ergonomic principles, WRMSDs and their risk factors, as well as manual handling techniques(Bolbol et al., 2017).
Study: NCT04969445

Intervention type: BIOLOGICAL
Intervention: Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)
Description: The bivalent HPV-16/18 vaccine was a mixture of two aluminum hydroxide adjuvant-absorbed recombinant L1 VLPs of HPV-16 and HPV-18 expressed in E. coli. A 0.5 ml dose of the bivalent HPV test vaccine comprised 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLPs absorbed with 208 μg of aluminum adjuvant
Study: NCT05315050

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational session and Information Pamphlet
Description: Each session will last for 50 minutes that will consist on lecturing, discussion about improving adolescent girls' menstrual knowledge, promoting a more positive attitude, encourage confidence, self-care behavior, physical activity and improve pain relief practice.~Exercise advice: The exercise protocol will include aerobic exercise such as jogging, which perform in the interventional group, three times a week, and for 10 to 30 min.~Stretching's advice: Piriformis stretching (5 repitition×20seconds), Cobra Pose. (5 repitition×20seconds), Adductor stretching. (5 repitition×20seconds), Sit up (10 repetition × 3 sets), Bridge exercise (10 repetition × 3 sets), Kegel exercise (10repetition × 3 sets), Pelvic eleva¬tion (10repetition × 3 sets), three times a week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Information Pamphlet
Description: Pamphlets consist of information about primary dysmenorrhea its causes, symptoms (onset, duration, location, prognosis) and treatment strategies (taking hot bath, heating pad, yoga, exercise, maintaining hygiene, modifying life style) Emphasized on that menstruation is a not a disease it's a natural life experience.
Study: NCT04973579

Intervention type: PROCEDURE
Intervention: Simutaneous (single anaesthesia) carotid artery stenting with MicroNet covered stent (CGuard) and cardiac surgery (CABG or surgical valve replacement / repair procedure)
Description: The registry enrolls patients qualified for treatment with the methods evaluated in the registry, using routinely applicable procedures and devices.~In cardiac surgery - surgical treatment systems for advanced ischemic heart disease and/or valvular disease (including - mechanical/biologic heart valves - regulatory approved for routine use and typically used at the Facility.~In the simultaneous treatment of stroke-threatening carotid artery atherosclerosis - temporary neuroprotection systems (proximal, distal, according to medical indications and local experience) - regulatory approved for routine use and typically used at the center (for over 20 years).~CGuard anti-embolic mesh stent system - a self-expanding nitinol carotid stent wrapped in MicroNet, which prevents fragments of atherosclerotic plaque from entering the lumen of the carotid artery - approved for routine use and typically used at the Center (over 5 years).
Study: NCT06238674

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: indirect calorimetry and nitrogen balance
Description: nutrition therapy with energy guided by indirect calorimetry measurements and total protein guided by nitrogen balance with the maximum of 1.3 g/kg/d~, repeated indirect calorimetry if renal replacement therapy was initiated and follow up of urea nitrogen balance after 7 days of intervention to guarantee positive nitrogen balance

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Indirect calorimetry (Standard care nutrition arm)
Description: indirect calorimetry measurements using the Q-NRG+ device will be conducted and urea nitrogen balance were measured . In the standard care nutrition arm, clinicians will be blinded to indirect calorimetry and urea nitrogen balance measurements
Study: NCT04540770

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HuL001
Description: Anti-ENO1 monoclonal antibody

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HuL001
Description: Anti-ENO1 monoclonal antibody

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HuL001
Description: Anti-ENO1 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HuL001
Description: Anti-ENO1 monoclonal antibody
Study: NCT06065176

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Novavax COVID-19 vaccine (2023-2024 formula XBB containing)
Description: Participants will receive a single dose of the Novavax vaccine.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pfizer COVID-19 mRNA vaccine (2023-2024 formula XBB containing)
Description: Participants will receive a single dose of the Pfizer vaccine.
Study: NCT05889455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Oral administration of 100mg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06493539

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care group
Description: The control group will receive standard of care wound treatment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CINPWT
Description: Subject will receive CINPWT until discharged
Study: NCT05053516

Intervention type: OTHER
Group type: OTHER
Intervention: A standardized training program for social workers
Description: A standardized training program for social workers who work with drug addicts / drug users based on industry needs

Intervention type: OTHER
Group type: OTHER
Intervention: A standardized training program for social workers
Description: A standardized training program for social workers who work with drug addicts / drug users based on industry needs
Study: NCT06234150

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic dance
Description: Patients assigned to the aerobic dance group will participate in a one-on-one training session before their first chemotherapy session, including aerobic dance instruction, teleconference participation, use of a heart rate bracelet, and use of the Perceived Exertion Rating (PRE) until they master all components. The researchers will also provide participants with instructional videos to view anytime. We will require an exercise log to record the number of workouts, the intensity of the workout using the PRE and heart rate, and the presence of adverse effects. An experienced physical therapist will remotely supervise patients via teleconferencing at home. They will exercise for 50 min three times per week for 12 weeks. The physiotherapist monitors the patient\&amp;#39;s heart rate throughout the exercise program and provides feedback on any problems encountered during exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fast-walking
Description: Patients assigned to the fast-walking group will participate in a one-on-one training session before their first chemotherapy session, including fast-walking instruction, teleconference participation, use of a heart rate bracelet, and use of the Perceived Exertion Rating (PRE) until they master all components. The researchers will also provide participants with instructional videos to view anytime. We will require an exercise log to record the number of workouts, the intensity of the workout using the PRE and heart rate, and the presence of adverse effects. An experienced physical therapist will remotely supervise patients via teleconferencing at home. They will exercise for 50 min three times per week for 12 weeks. The physiotherapist monitors the patient\&amp;#39;s heart rate throughout the exercise program and provides feedback on any problems encountered during exercise.
Study: NCT06387121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Anti-tumor alkaloids

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Anti-tumor alkaloids

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Alkylating agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Alkylating agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Glucocorticoids

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Glucocorticoids

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Selective inhibitor of B-cell lymphoma 2 (Bcl-2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Selective inhibitor of B-cell lymphoma 2 (Bcl-2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin
Description: A humanized monoclonal antibody-drug conjugate targeting CD22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Bi-specific anti-CD19/CD3 antibodies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-mercaptopurine
Description: Cell cycle-specific antitumor drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-mercaptopurine
Description: Cell cycle-specific antitumor drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Antifolate antineoplastic drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Antifolate antineoplastic drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Pyrimidine antimetabolites

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Pyrimidine antimetabolites

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Glucocorticoids

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Glucocorticoids
Study: NCT05411549

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet Modification to Adopt Mediterranean Diet
Description: Participants enrolled in group 1 will be counselled by a dietician and asked to adopt a Mediterranean diet for a 12-week period from counselling. Participants will complete a series of Mediterranean Diet Adherence Score, pain questionnaires as well as quality of life questionnaires (EPH-30, SF-36, GIQLI) which have been previously validated. Participants in this group will give a baseline and final visit blood sample and stool samples to assess inflammation biomarkers as well as gut microflora.
Study: NCT05972382

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative Sensory and Neurophysiological Testing
Description: Participants will undergo the following quantitative sensory and neurophysiological diagnostic tests:~Surface electromyography (EMG) of the neck flexor muscles during the craniocervical flexion test to assess neck flexor muscle fatigue. EMG sensors will be placed over the sternocleidomastoid and longus colli muscles. Cervical joint position error testing to evaluate proprioceptive awareness and cervicocephalic kinesthetic sensibility. Participants will be seated upright and blindfolded.
Study: NCT05102578

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Decision Aid Tool
Description: The digital DAT will ask people about their current pain levels, medications and physical activity. Following this, it will include a Discrete Choice Experiment (DCE)-like component with a series of questions that ask users to choose between different pain management packages. Similar to a standard DCE, packages (or plans) are described by attributes and levels, which include broad categories of guideline-based pain management strategies routinely available in clinical practice. The descriptors used for the attributes and levels were informed by a previous qualitative research study and based on therapeutic options that are helpful and important to people with persistent pain .
Study: NCT06116227

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration Training Plus Conventional Physical Therapy Exercise Program.
Description: Patients in the study group will receive the traditional physical therapy program first, followed immediately by whole-body vibration training on the vibration platform (Power Plate International, Irvine, California, USA) at the same visit. The vibration frequency will be 30 Hz and the amplitude will be from 4 to 7 mm, with an increase of 1mm every two weeks. The WBV program was three sessions a week for eight weeks. WBV duration starts with 10 min in the 1st week and up to 25 min in the 8th week, with a regular increase of five minutes after every two successive weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Physical Therapy Exercise Program.
Description: The program will include 60 minutes of a supervised and individualized exercise program, including stretching exercises for the Calf and hamstring muscles, followed by strengthening exercises for hip, knee, ankle, and foot muscles, and scar management techniques to avoid scar or contracture formation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Physical Therapy Exercise Program.
Description: The program will include 60 minutes of a supervised and individualized exercise program, including stretching exercises for the Calf and hamstring muscles, followed by strengthening exercises for hip, knee, ankle, and foot muscles, and scar management techniques to avoid scar or contracture formation.
Study: NCT05661227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Whether apply DEX or not

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: 0.9% Sodium chloride
Description: Whether apply DEX or not

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tourniquet(Early)
Description: Timing of tourniquet application

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tourniquet(Late)
Description: Timing of tourniquet application
Study: NCT05638451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab plus Bevacizumab and Temozolomide
Description: 200mg Sintilimab plus 10mg/kg Bevacizumab very 3 weeks 200 mg/m2/day Temozolomide on days 1-5 out of a 28 days schedule
Study: NCT05188820

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRP - platelet rich plasma injection
Description: Facet block using PRP

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cortisone injection
Description: Facet block using cortisone
Study: NCT06027736

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacist-led education
Description: A patient education protocol and an algorithm of pharmaceutical care in managing allergic rhinitis.
Study: NCT05864742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: 560 mg daily continuously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: 560 mg daily continuously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Oral daily. Dose escalation every 7 days (if no TLS) 20mg, 50mg, 100mg, 200mg and 400mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Oral daily. Dose escalation every 7 days (if no TLS) 20mg, 50mg, 100mg, 200mg and 400mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navitoclax
Description: Oral daily. Dose-escalation every 14 days (if plt \>75x10\^9/L) 50mg, 100mg, 150mg, and 200mg (target dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375mg/m2, intravenous. To be given on day 1 of weeks 1, 2, 3, 4 of C1 and day 1 of C2-C8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375mg/m2, intravenous. To be given on day 1 of weeks 1, 2, 3, 4 of C1 and day 1 of C2-C8
Study: NCT06343935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linperlisib
Description: Linperlisib is a small molecule inhibitor of phosphoinositol 3-kinase-δ (PI3K-δ)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linperlisib
Description: Linperlisib is a small molecule inhibitor of phosphoinositol 3-kinase-δ (PI3K-δ)
Study: NCT05533879

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tele-yoga
Description: Women with chronic low back pain will be taken to group-based Tele-Yoga sessions of 60 minutes three times a week for 4 weeks, in an internet-based telerehabilitation environment.
Study: NCT05708950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KVA12123 - Dose Escalation
Description: Ascending KVA12123 doses given as monotherapy by intravenous administration every 2 weeks of each 6-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KVA12123 Plus Pembrolizumab - Dose Escalation
Description: Ascending KVA12123 doses given by intravenous administration every 2 weeks of each 6-week cycle in combination with a fixed dose of pembrolizumab administered once every 6 week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KVA12123 - Dose Expansion
Description: KVA12123 administered at the RP2D by intravenous administration every 2 weeks of each 6 week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KVA12123 Plus Pembrolizumab - Dose Expansion
Description: KVA12123 administered at the RP2D by intravenous administration every 2 weeks in combination with a fixed dose of pembrolizumab administered once every 6 week cycle.
Study: NCT06110260

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AstraGin (Ginseng and Astragalus Saponin Extract)
Description: In this study, we are investigating the effects of AstraGin on healthy adults. The testing sample is orally administrated to subjects with 35g whey protein + AstraGin. After intervention, a 180-min kinetics study of plasma amino acids was conducted.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In this study, we are investigating the effects of AstraGin on healthy adults. The testing sample is orally administrated to subjects with 35g whey protein + Placebo. After intervention, a 180-min kinetics study of plasma amino acids was conducted.